Great Plains Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• DUAL-ACS: 12-Month vs. 3-Month DAPT Following Acute MI
  Findings from the DUAL-ACS trial presented at ESC Congress 2025 suggest that three months of dual antiplatelet therapy (DAPT) following an acute myocardial infarction (MI) has the potential for better survival and lower bleeding rates compared with 12 months of DAPT.
• OPTION-STEMI: Immediate vs. Staged Complete Revascularization in Patients With STEMI and Multivessel CAD
  Noninferiority was not demonstrated in the OPTION-STEMI trial comparing immediate complete revascularization with staged complete revascularization in patients with STEMI and multivessel coronary artery disease. The findings, simultaneously published in The Lancet, were presented at ESC Congress 2025.
• Novel Adipokine Hypothesis Offers Framework to Explain Pathogenesis and Guide Treatment of HFpEF
  Heart failure with preserved ejection fraction (HFpEF) appears to arise “primarily from the expansion and dysfunctional transformation of visceral adipose tissue, leading to the secretion of altered suite of signaling molecules (adipokines), which causes systemic inflammation, plasma volume expansion, and cardiac hypertrophy and fibrosis,” according to the Adipokine Hypothesis authored by Milton Packer, MD, FACC, […]
• AQUATIC: Aspirin Plus OAC Results in Higher Risk of Major CV Events and Bleeding in Patients With Chronic Coronary Syndrome
  Patients with chronic coronary syndrome and at high atherothrombotic risk who received aspirin in addition to their current oral anticoagulation therapy had a higher risk of cardiovascular death, myocardial infarction, stroke, systemic embolism, coronary revascularization, or acute limb ischemia than those taking a placebo, according to results from the AQUATIC study presented at ESC Congress […]
• PULSE: Does CCTA After PCI For Unprotected Left Main Disease Reduce Major CV Events?
  Coronary computed tomography angiography (CCTA) following PCI for unprotected left main disease did not reduce the composite primary endpoint of all-cause death, spontaneous myocardial infarction (MI), unstable angina, or definite or probable stent thrombosis at 18 months, based on findings from the PULSE trial presented at ESC Congress 2025 and simultaneously published in JACC.